- Home
- CDNA vs GHRS Comparison
CDNA vs GHRS Comparison
Compare CDNA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDNA | GHRS |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CDNA | GHRS |
|---|---|---|
| Price | $20.42 | $16.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $26.67 | ★ $32.90 |
| AVG Volume (30 Days) | ★ 723.7K | 681.3K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $357,998,000.00 | N/A |
| Revenue This Year | $14.47 | N/A |
| Revenue Next Year | $11.35 | N/A |
| P/E Ratio | $16.81 | ★ N/A |
| Revenue Growth | ★ 14.46 | N/A |
| 52 Week Low | $10.96 | $7.98 |
| 52 Week High | $25.55 | $20.50 |
Technical Indicators
Market Signals| Indicator | CDNA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 58.08 |
| Support Level | $19.48 | $15.48 |
| Resistance Level | $21.49 | $17.30 |
| Average True Range (ATR) | 1.18 | 1.64 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 76.57 | 55.82 |
Price Performance
Historical ComparisonAbout CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.